Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Malignant Gliomas
NCT00669669Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2009
- Primary completion
- Jul 2018
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of 6-benzylguanine in glioblastoma multiforme (GBM), Gliosarcoma (GS), sponsored by Fred Hutchinson Cancer Center. Started Feb 2009; status: terminated.
02
Drugs
6-benzylguanine
03
Conditions
glioblastoma multiforme (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00669669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00669669.